Biomedical progress in therapeutics has been hindered despite advances in basic science, a trend known as Eroom's Law. The Clinical Trial Abundance Project aims to enhance the efficiency and informativeness of clinical trials, arguing that learning from both successes and failures is crucial for developing new therapies, as exemplified by the evolution of CAR-T cell therapies.

An experimental drug has shown promising results by significantly reducing stealthy cholesterol levels with just a single dose. This breakthrough could have substantial implications for cardiovascular health and treatment options in the future.